



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_304_25

You asked:

I am writing to you under the Freedom of Information Act 2000 to request the following information:

1. Is your health board currently treating myeloma patients

Yes.

2. Please list the hospitals in your board that are currently treating myeloma patients.

Prince Charles Hospital and the Royal Glamorgan Hospital. Patient's from the Bridgend area are referred to [Swansea Bay University Health Board](#) for treatment.

3. Please list how many myeloma patients are being treated by your board. Please break this down by hospital.

80 patients – 40 patients in Prince Charles Hospital, 40 patients in the Royal Glamorgan Hospital.

4. Is your health board currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital.

No patients currently on treatment.

5. Please list how many people have been given

a) elranatamab

b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015. If possible, please break this down by hospital.

a) elranatamab – *Less than 5.

b) Teclistamab – Zero

*The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6,

and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

6. Do you have a service level agreement or referral system in place with any other health boards to deliver a) elranatamab or b) teclistamab to patients.

No formalised process for referral. Patients are considered for treatment on individual basis by [Cardiff and Vale University Health Board](#) (C&V UHB). For further information you will need to contact C&V UHB directly.

7. If the answer to this question is yes, which health boards do you have an agreement in place with.

As above.